Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
IN8bio (INAB)
NASDAQ:INAB
Holding INAB?
Track your performance easily
INAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.22 - $1.93
Previous Close$0.25
Volume1.33M
Average Volume (3M)1.22M
Market Cap
$17.42M
Enterprise Value$18.90M
Total Cash (Recent Filing)$4.00M
Total Debt (Recent Filing)$5.47M
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Mar 13, 2025EPS Estimate
-$0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding72,483,253
10 Day Avg. Volume475,134
30 Day Avg. Volume1,220,459
Standard Deviation0.29
R-Squared0.00
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)2.07
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.66
Forecast
1Y Price Target
$8.00Price Target Upside3115.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
IN8bio News
PremiumCompany Announcements
IN8bio Advances Cancer Therapies Amid Financial Restructuring
PremiumCompany Announcements
IN8bio Revises Executive Compensation and Severance Terms
Bulls Say, Bears Say
Bulls Say
Clinical OutcomesThe updated data shows that patients receiving repeat INB-200 doses demonstrated a significant increase in median progression-free survival compared to the standard treatment.
Financial ProspectsPotential partnership opportunities for INB-200 could provide non-dilutive cash, offering financial benefits without diluting shareholder value.
Therapeutic AdvancementsPhysicians are excited about the potential of INB-200 at the oral plenary session, highlighting the promising infiltration of gamma-delta T cells in tumors and the benign safety profile.
Bears Say
Clinical TrialsThere is a lack of a control arm and comparison with historical data, which is unlikely to benefit the stock as follow-ups continue.
Financial PerformanceCapital overhang remains the key concern, with the company having $10.2 million in cash and equivalents and a cash burn rate exceeding $6 million per quarter.
Strategic PrioritizationThe company announced their prioritization of INB-100 for AML and suspension of clinical trial enrollment for their INB-200 and '400 GBM programs.
---
Ownership Overview
32.66% Insiders
2.40% Mutual Funds
6.55% Other Institutional Investors
56.35% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
INAB FAQ
What was IN8bio’s price range in the past 12 months?
IN8bio lowest stock price was $0.22 and its highest was $1.93 in the past 12 months.
What is IN8bio’s market cap?
Currently, no data Available
When is IN8bio’s upcoming earnings report date?
IN8bio’s upcoming earnings report date is Mar 13, 2025 which is in 81 days.
How were IN8bio’s earnings last quarter?
IN8bio released its earnings results on Nov 12, 2024. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.17 by $0.02.
Is IN8bio overvalued?
According to Wall Street analysts IN8bio’s price is currently Undervalued.
Does IN8bio pay dividends?
IN8bio does not currently pay dividends.
What is IN8bio’s EPS estimate?
IN8bio’s EPS estimate is -$0.07.
How many shares outstanding does IN8bio have?
IN8bio has 72,483,250 shares outstanding.
What happened to IN8bio’s price movement after its last earnings report?
IN8bio reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.17. Following the earnings report the stock price went down -8.571%.
Which hedge fund is a major shareholder of IN8bio?
Among the largest hedge funds holding IN8bio’s share is Wela Strategies, Inc.. It holds IN8bio’s shares valued at N/A.
---
IN8bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (3115.43% Upside)
$8.00 (3115.43% Upside)
Hedge Fund Trend
Decreased
By 18.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.28%
12-Months-Change
Fundamentals
Return on Equity
-241.97%
Trailing 12-Months
Asset Growth
-39.08%
Trailing 12-Months
Company Description
IN8bio
IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.
---
INAB Stock 12 Month Forecast
Average Price Target
$8.00
▲(3115.43% Upside)
Technical Analysis
Best Analysts Covering INAB
1 Year
1 Year Success Rate
0/15 ratings generated profit
1 Year Average Return
-57.67%
reiterated a buy rating 26 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -57.67% per trade.
---